Dragon Pharmaceutical Inc. (Dragon Pharma) is an pharmaceutical company. Dragon Pharma produces and supplies antibiotic products including Clavulanic Acid, 7-ACA, downstream cephalosporin active pharmaceutical ingredient (API) and formulated powder for injection in both Chinese and emerging markets. The Company has three production facilities in Datong, China. On January 1, 2008, the Company has realigned its business segments into two divisions: Cephalosporin and Penicillin. (Source: 10-K)
Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Of its six programs in development, four are in late stage: its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas Pharma Inc. (Astellas), its Horizon program (formerly referred to as Beyond Advair) with GlaxoSmithKline plc (GSK), its Gastrointestinal Motility Dysfunction program, and TD-1792, its investigational antibiotic for the treatment of serious Gram-positive bacterial infections. (Source: 10-K)
TopoTarget A/S is a Denmark-based biotech company. It is focused on treatments for cancer patients and other cancer-related disorders. Its activities cover various aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, business development and marketing and sales. TopoTarget’s main product is Savene/Totect. Its clinical pipeline has six drug candidates in Phase II: a clinical compound belinostat (PXD101), oncology products APO866, Siramesine, Baceca, Savicol and the non-oncology drug candidate Avugane. Additionally, it has three oncology products in Phase I development (Zemab, APO010 and Topotect). The Company also has a number of earlier stage cancer products in pre-clinical development, including HDAC inhibitors, as well as HSP90 and mTOR modulators. TopoTarget has operations in Denmark, the United States, Switzerland, the United Kingdom and Germany.
Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry. Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery including access to biological models as well as both small-molecule and secreted protein drug targets. In addition, Deltagen offers extensive target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals and Pfizer.
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. We currently have four product candidates in development: one to prevent travelers? diarrhea and three targeting influenza and pandemic flu.
Genaera Corporation (Genaera) is a biopharmaceutical company dedicated to developing medicines to address substantial unmet medical needs in pharmaceutical markets. The Company's research and development efforts are focused on metabolic disorders. Its lead clinical drug candidate, trodusquemine (MSI-1436), is being developed to treat obesity and type 2 diabetes. In addition to MSI-1436, Genaera has a collaborative agreement with MedImmune, Inc. to develop and commercialize therapies related to the Company's anti-interleukin-9 (IL9) program for the treatment of asthma. It also has an exclusive license with Laboratorios Bago to develop and market Lomucin (talniflumate) as a mucoregulator drug. As of December 31, 2007, Genaera had not generated revenue from its product sales. (Source: 10-K)
AXYS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, design and development of therapeutic small molecules that address significant markets with major unmet medical needs. AXYS collaborates with large pharmaceutical companies in discovering therapeutics for chronic diseases for which there are large markets. Currently, the Company has significant collaborations with Aventis Pharmaceuticals Product, Inc. (a subsidiary of Aventis S.A.), Merck & Co. and Bayer A.G. The Company also selectively focuses its own resources on discovering and developing therapeutics for the treatment of various types of cancer and other specialty market therapeutics. The Company has on-going programs in the treatment of autoimmune, inflammatory diseases, and cancers. (Source: 10-K)
CombinatoRx, Incorporated is a biopharmaceutical company focused on developing synergistic combinations pharmaceuticals, with a portfolio of product candidates in phase II clinical development. The Company creates product candidates with mechanisms of action striking at the biological complexities of human disease. The principal programs in its portfolio are advancing into later stage clinical trials. This portfolio is internally generated from CombinatoRx, Incorporated’s combination high throughput screening (cHTS) technology, which provides a renewable and previously untapped source of drug candidates. The Company is developing a clinical portfolio of product candidates targeting multiple diseases, including immuno-inflammatory diseases, topical dermatoses and metabolic disease. (Source: 10-K)
SUGEN, Inc. is a biopharmaceutical company focusing on the development of new classes of small molecule drugs which interact in a specific manner with different members of the tyrosine kinase, serine-threonine kinase and tyrosine phosphatase families of signal transduction molecules, and their signalling pathways. These pathways are involved in a number of human diseases including cancer and diabetes, as well as disorders of the body's immune defenses and neurological systems. The Company has research and development collaborations with Zeneca, ASTA Medica and Allergan.
CV Technologies Inc. is a life sciences and technology company. The Company has developed and commercialized ChemBioPrint, which is used to discover and biologically standardize natural products. Using the ChemBioPrint discovery and standardization platform, the Company's scientists are able to identify precisely the chemical profile and biological activity of natural products. The process involves a combination of chemical and biological fingerprinting. The Company’s three principal product lines are COLD-fX, which helps reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system; REMEMBER-fX, which helps enhance mental alertness, and CELL-fX, which helps relieve symptoms of bone and joint pain and assists in the formation of connective tissue. All the Company’s products are designed to support normal physiological/body functions with a natural formula. (Source: ARS)
Large Scale Biology Corporation's (LSBC) goal is to develop, manufacture and commercialize plant-made pharmaceutical proteins and vaccines. LSBC has successfully garnered an international reputation as an innovator in biomanufacturing. Driven by its unique GENEWARE® RNA plant viral gene expression technology, LSBC has taken integration of plant-made pharmaceuticals from gene to production further than any other company. GENEWARE® technology is complemented by a full commercial-scale capability to produce, extract, purify, finish and fill a wide range of pharmaceutical proteins. LSBC's proprietary core technologies radically extend the power of product development, improvement and manufacture. LSBC is pursuing an aggressive, market-oriented business model designed to take full advantage of its technological lead and its ability to integrate all major components in the product pipeline. LSBC's technologies and discoveries are protected by an extensive portfolio of foreign and domestic patents, and the company has formed several major alliances and partnerships to maximize its market opportunities. LSBC's ability to bring innovative tools to the forefront of the life sciences industry is well documented, and the company can proudly claim a number of industry firsts, including: the first practical plant-virus-based manufacturing platform, the first release of a safe, transgenic virus into a controlled outdoor environment under government permit, the world's first cancer vaccine made in plants by any expression technology, and the first virus-based multi-component vaccine platform. LSBC's activities are conducted in two locations in the United States, with a network of collaborators and affiliates throughout the US and Europe. The Company's headquarters and R&D facilities are in Vacaville, California, and its Biomanufacturing Division is located in Owensboro, Kentucky.
deCODE genetics, Inc. (deCODE) is a biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. The Company’s population approach and resources enable the Company to isolate genes and drug targets directly involved in the development of the diseases posing challenges to public health. deCODE is turning these discoveries into a growing pipeline of diagnostic tests and therapeutics taking aim at the causes of disease, not just the signs and symptoms. deCODE also offers its consumer genetic analysis service deCODEme. deCODEme enables individual subscribers to have their genome analyzed with approximately one million single-letter markers (SNPs), and to view, on their own secure personal Web interface, whether they carry genetic variants linked by the Company and others to risk of a growing list of common diseases, and to see what their genome can tell them about their ancestry and a number of other non-medical traits. (Source: 10-K)
BioXell SpA is an Italy-based biopharmaceutical company. The Company focuses on the research, development and commercialization of therapies for various medical needs. It is active in a range of therapeutic areas, such as urology (benign prostatic hyperplasia, overactive bladder and male infertility), inflammation (sepsis, inflammatory bowel disease, post-surgical adhesions), pain and other therapeutic areas (secondary hyperparathyroidism and osteoporosis). BioXell S.p.A’s products, which are in the preclinical and development phases, include Elocalcitol and BXL746, a Vitamin D3 analogues for the treatment of urological disorders; MNAC13 applied for treatment of chronic pain, and TREM-1, for the treatment of sepsis. The Company has one wholly owned subsidiary, BioXell Inc that develops the Vitamin D3 platform.
Caprion offers its employees a dynamic and stimulating work environment, encouraging continuous innovation and the sharing of knowledge and ideas. We offer a comprehensive compensation package, including a competitive salary, participation in an employee stock option plan, a group insurance plan and relocation assistance. Our 54,000 square foot world-class proteomics facility is situated in the Technoparc of St-Laurent, Quebec and includes a fitness center, coffee bar, employee lounge and other exciting amenities. We are in close proximity to Pierre-Elliot Trudeau International Airport, and downtown Montreal. Montreal is a unique urban environment, culturally rich, ethnically diverse and economically modern and dynamic.
Vernalis is a development stage pharmaceutical company with significant expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development. The Group has seven product candidates in clinicl development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other competitive research programmes.
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focusing on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The Company's principal programs are directed toward gastroenterology, virology and oncology. In the area of gastroenterology, its work is focused on methylnaltrexone, which is its principal product candidate. In the area of virology, Progenics is developing viral-entry inhibitors for human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), and Hepatitis C virus infection (HCV). In the area of prostate cancer, the Company is developing a human monoclonal antibody-drug conjugate, consisting of a selectively targeted cytotoxic antibody directed against prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. (Source: 10-K)
Endovasc, Inc. is a business development company focused on drug development in the areas of cardiovascular and metabolic medicine. The Company’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. The Company’s products include Liprostin and PROStent.
Amphora Discovery is a leading provider of integrated services for the pharmaceutical industry. We employ cutting-edge chemogenomic, systems biology and microfluidics technologies to deliver innovative and targeted lead generation and lead optimization solutions for our customers. Our mission is to enhance and improve the efficiency of our clients' discovery efforts through a process that shortens traditional timelines. The Company, headquartered in Research Triangle Park, North Carolina, USA, began operations in early 2002. Since our inception, we have built a cutting-edge drug discovery platform based on high precision microfluidic technology that delivers on the promise of shortening and improving lead generation and lead optimization processes. Our state-of-the-art research facility (shown below) has a flexible capacity to screen 1 million wells per week in an efficient, validated and automated process. This platform is built on quality principles that employ validated and optimized processes to provide extremely high quality data and thereby reduce timelines and costs. Amphora Discovery's products and services include in vitro assay protocols, optimized in vitro high throughput screening and compound profiling services, custom assay development, expert enzymology services and lead discovery/lead optimization partnering programs. Our clients include major pharmaceutical and biopharmaceutical companies, emerging biotechnology companies and major research foundations worldwide. Click here to download a corporate overview document.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory